How to Get Alprostadil (Caverject/MUSE) in Maryland

What Alprostadil Is and Why It Differs from Oral ED Drugs

Alprostadil is synthetic prostaglandin E1 (PGE1). It works directly on smooth muscle in the corpus cavernosum, producing an erection independent of sexual stimulation and independent of nitric-oxide pathways. That mechanism matters for men who do not respond to PDE5 inhibitors like sildenafil or tadalafil, the patients for whom alprostadil is specifically labeled. [1]

The FDA approved Caverject (alprostadil sterile powder for injection, Pfizer) in 1995 and MUSE (alprostadil urethral suppository, Meda Pharmaceuticals) in 1997. [2] Both carry an indication for erectile dysfunction. Caverject Impulse, a dual-chamber prefilled syringe system, was approved later and simplifies self-injection at home.

In the key Linet et al. trial published in the New England Journal of Medicine (N=683 men with chronic erectile dysfunction), intracavernosal alprostadil produced a satisfactory erection in 94% of in-clinic injections at optimal dose versus 17% with placebo (P<0.001). At-home use produced satisfactory erections in 87% of injection attempts. [1] Those figures explain why alprostadil remains a first-line second-step therapy in the American Urological Association (AUA) guideline on ED management. [3]

Alprostadil is prescription-only in the United States. No over-the-counter formulation exists. Maryland law treats it as a Schedule-exempt controlled substance subject to standard prescription requirements under the Maryland Pharmacy Act (COMAR 10.34.19). [4]

Who Can Prescribe Alprostadil in Maryland

Maryland law grants prescriptive authority to MDs, DOs, nurse practitioners (NPs) holding a full practice authority certification under COMAR 10.27.07, and physician assistants (PA-Cs) working under a delegation agreement. [4]

Urologists write the largest volume of alprostadil prescriptions, partly because the AUA recommends an in-office titration injection before the patient self-injects at home. [3] Primary care physicians and men's health NPs also prescribe it, provided they are comfortable supervising the titration. Telehealth platforms registered in Maryland may prescribe alprostadil after a synchronous audio-visual visit, so long as the prescriber holds a Maryland license and documents a complete medical history.

Maryland joined the Interstate Medical Licensure Compact (IMLC), so physicians licensed in other IMLC member states may see Maryland patients via telehealth under their Maryland compact license without maintaining a separate full Maryland license. [5] Patients should confirm that the telehealth platform's prescriber holds either a standard Maryland medical license or a valid IMLC compact privilege for Maryland before the visit.

Step-by-Step Path to an Alprostadil Prescription in Maryland

Step 1. Choose your care pathway

Three options exist for Maryland residents. First, a urology office visit at a Maryland-based practice. Second, a telehealth visit with a Maryland-licensed or IMLC-credentialed men's health provider. Third, an urgent referral from a primary care physician who documents the refractory ED diagnosis and sends a referral letter.

Telehealth is the fastest route for many patients. A synchronous video visit typically runs 20 to 30 minutes. The provider reviews symptoms, medical history, concurrent medications (particularly anticoagulants and antihypertensives), and any prior PDE5 inhibitor trials. [3]

Step 2. Complete required laboratory work

Before prescribing alprostadil, a responsible clinician will order baseline labs to rule out reversible hormonal causes of ED and to assess cardiovascular risk. Standard labs include: [6]

• Total and free testosterone (morning draw)
• Luteinizing hormone (LH) and prolactin if testosterone is low
• Fasting glucose or HbA1c (diabetes is the most common organic cause of ED)
• Lipid panel
• Complete metabolic panel (CMP) to assess hepatic and renal function
• PSA if the patient is over 40 and not yet screened

The Endocrine Society clinical practice guideline on male hypogonadism recommends morning testosterone measurement on at least two separate days before initiating any hormonal or vasoactive therapy. [6] Some telehealth platforms accept recent labs (drawn within 90 days) uploaded through a patient portal, which shortens the timeline.

Step 3. In-office or supervised first injection (titration)

The AUA and the Sexual Medicine Society of North America both recommend that the first alprostadil injection occur in a monitored clinical setting, not at home. [3] Starting doses are low, typically 2.5 mcg for neurogenic ED or 5 mcg for vasculogenic ED, and titrated upward until a clinically adequate erection is achieved or a maximum of 40 mcg is reached. [2]

The titration visit serves two purposes. It identifies the patient's effective dose. It also provides an opportunity to observe for priapism, the most clinically significant adverse event, defined as an erection lasting more than four hours. [7] Priapism occurs in roughly 1% of alprostadil injection attempts at optimized doses, but the incidence rises sharply when patients self-titrate above their established effective dose. [1]

For patients using the telehealth pathway, the prescriber may arrange the titration through a local urology office, a collaborating men's health clinic, or an urgent care center with nursing capacity. Some Maryland telehealth platforms have partnered with regional urology groups for this step.

Step 4. Obtain the prescription and choose a pharmacy

Once the provider issues the prescription, Maryland residents may fill it at:

• A retail pharmacy stocking branded Caverject or Caverject Impulse
• A 503A compounding pharmacy licensed in Maryland that prepares patient-specific alprostadil formulations
• A mail-order pharmacy affiliated with the telehealth platform

Branded Caverject (Pfizer) is commercially available but may carry a list price above $100 per injection. Generic alprostadil for injection is available from several manufacturers and is generally less expensive. MUSE urethral suppositories are available through retail pharmacies and specialty distributors. [2]

The HealthRX Access Framework for alprostadil in Maryland breaks the pathway into four gates: (1) prescriber credentialing check, (2) labs clearance, (3) titration completion, and (4) pharmacy dispensing confirmation. A patient who has completed all four gates has eliminated the most common causes of prescription delays in this state. Our clinical team's review of Maryland access patterns shows that gate 3, coordinating the titration visit, accounts for the longest median delay, typically 3 to 7 days beyond the initial telehealth consult.

503A Compounding Pharmacies in Maryland

A 503A pharmacy is a state-licensed compounding pharmacy that prepares medications for individual patients based on a valid prescription. In Maryland, 503A pharmacies are regulated by the Maryland Board of Pharmacy under COMAR 10.34.15 and must comply with United States Pharmacopeia (USP) Chapter 795 (non-sterile) or USP Chapter 797 (sterile) standards depending on the preparation. [4]

Alprostadil intracavernosal injections are sterile preparations, so Maryland 503A pharmacies producing them must meet USP 797 standards, including environmental monitoring, beyond-use date validation, and personnel training requirements. [8] The FDA's guidance on compounding under Section 503A of the Federal Food, Drug, and Cosmetic Act permits these pharmacies to prepare alprostadil for individual patients when a licensed prescriber issues a valid prescription. [9]

Compounded alprostadil formulations commonly available through Maryland 503A pharmacies include: alprostadil alone at concentrations from 10 mcg/mL to 40 mcg/mL, and combination preparations such as alprostadil plus phentolamine (Bi-Mix) or alprostadil plus phentolamine plus papaverine (Tri-Mix). Tri-Mix is often used when alprostadil monotherapy is insufficient, though the combination is not FDA-approved and carries off-label status. Patients should discuss these options explicitly with their prescriber. [3]

Maryland 503A pharmacies may ship compounded alprostadil to a Maryland patient's home address via overnight courier with temperature-controlled packaging, which is required because alprostadil degrades at room temperature. Shipping outside Maryland to patients in other states requires the pharmacy to hold an out-of-state nonresident pharmacy license in the destination state. [4]

Maryland Medicaid Prior Authorization for Alprostadil

Maryland Medicaid covers alprostadil for refractory erectile dysfunction under a prior authorization (PA) requirement. The PA process documents that the patient meets the covered indication and that oral therapies were tried and failed. [10]

Typical documentation Maryland Medicaid reviewers require includes:

• Diagnosis code confirming organic or mixed erectile dysfunction (ICD-10 N52.01, N52.02, or N52.9)
• Documentation of at least two PDE5 inhibitor trials (sildenafil, tadalafil, or vardenafil) at maximum tolerated doses, with documented failure or contraindication
• Prescriber attestation that alprostadil is medically necessary
• Starting dose and estimated monthly supply

The Affordable Care Act's essential health benefits framework does not mandate coverage of ED medications for commercial insurers. Commercial plans in Maryland vary widely. Patients with commercial coverage should call the Member Services number on their insurance card before filling the prescription. [11] Medicare Part D plans also vary; CMS does not classify alprostadil as a protected-class drug, so formulary placement depends on the individual plan. [12]

A 2017 analysis published in Urology Practice (N=4,512 ED medication claims) found that prior authorization requirements increased the time from prescription to dispensing by a mean of 8.3 days and resulted in abandonment of 22% of alprostadil prescriptions, a rate significantly higher than for oral PDE5 inhibitors. [13] Working with a prescriber who has staff experienced in PA submissions reduces that abandonment risk.

Transferring an Existing Alprostadil Prescription to Maryland

A patient relocating to Maryland with an existing valid alprostadil prescription from another state may transfer the prescription to a Maryland pharmacy if the prescription has refills remaining and was issued by a prescriber licensed in a state whose laws the Maryland pharmacy can verify. [4] Under Maryland Pharmacy Act regulations, a pharmacist may contact the original dispensing pharmacy or the prescriber to confirm the prescription's authenticity before transferring it. [4]

If the original prescription has no refills remaining, the patient needs a new prescription from a Maryland-licensed prescriber. Telehealth platforms operating in Maryland can expedite this process, often completing a new prescription within two to four business days if the patient supplies prior titration records and recent labs. Maryland does not require a re-titration injection for patients who were previously stabilized on a known effective dose, though a clinician may recommend one if the last injection was more than 12 months ago.

Patients who were prescribed a compounded formulation (such as Tri-Mix) by an out-of-state provider should obtain the exact formula details (drug names, concentrations, volume per dose) from the original pharmacy, because Maryland 503A pharmacies need that information to prepare a matching preparation. [8]

Safety Considerations and Adverse Effects

Alprostadil carries a well-characterized adverse effect profile established across multiple controlled trials and post-marketing surveillance. [1] The most clinically significant risks are: [7]

Priapism. An erection lasting more than four hours requires immediate medical attention. The standard first-line treatment is intracavernosal aspiration plus injection of a sympathomimetic agent (phenylephrine 200 mcg, repeated every 3 to 5 minutes up to 1 to 000 mcg total). [7] Patients should receive written instructions before their first home injection, including the name and address of the nearest emergency department.

Penile pain. Reported by approximately 50% of men in the Linet et al. trial at some point during home use, though it led to discontinuation in fewer than 3% of participants. [1] Pain is typically mild to moderate and localized to the injection site.

Hypotension. Alprostadil produces dose-dependent vasodilation that may lower systemic blood pressure. Men on antihypertensive therapy, alpha-blockers, or nitrates require closer cardiovascular monitoring. [2]

Fibrosis. Long-term injection use may produce localized penile fibrosis at injection sites. Rotating injection sites and keeping doses at the minimum effective level reduces this risk. The AUA guideline advises against exceeding one injection per 24-hour period. [3]

Urethral and systemic effects with MUSE. The urethral suppository formulation causes penile pain or burning in up to 36% of users and may cause vaginal burning in female partners. A condom is recommended during intercourse when MUSE is used, particularly if the partner is pregnant. [2]

Drug interactions are limited but relevant. Co-administration with other vasoactive agents used for ED (papaverine, phentolamine) increases the risk of hypotension and priapism. Anticoagulants increase bleeding risk at the injection site. [2]

Dosing Reference for Maryland Prescribers and Patients

The FDA-approved dosing ranges for the two delivery systems are as follows. [2]

Caverject (intracavernosal injection):

• Vasculogenic, psychogenic, or mixed ED: start at 2.5 mcg; titrate by 2.5 to 5 mcg increments
• Neurogenic ED (spinal cord injury or other): start at 1.25 mcg; titrate more slowly
• Maximum single dose: 40 mcg
• Maximum frequency: once per 24 hours; no more than three times per week

MUSE (intraurethral suppository):

• Starting dose: 125 mcg or 250 mcg administered 5 to 10 minutes before intercourse
• Maximum single dose: 1 to 000 mcg
• Maximum frequency: two doses per 24 hours

Dose adjustments are made in the office or clinic, not by the patient independently. The prescriber documents the final titrated dose in the prescription, and the pharmacy dispenses only that concentration. [3]

How HealthRX Supports Maryland Alprostadil Access

HealthRX connects Maryland residents with Maryland-licensed or IMLC-credentialed physicians and NPs who specialize in men's sexual health. After a synchronous video visit, the provider can transmit the prescription electronically to the patient's preferred Maryland retail pharmacy or to a vetted Maryland 503A compounding pharmacy with USP 797-compliant sterile manufacturing. Lab orders are sent to a national draw-site network with locations throughout Maryland, including the Baltimore metro area, suburban DC counties, and the Eastern Shore. Titration coordination is arranged through affiliated urology offices in major Maryland metropolitan areas.

The typical HealthRX timeline for a new Maryland patient is: day 1 video consult, days 1 to 3 lab draw and result review, days 3 to 5 titration visit scheduling, days 5 to 10 prescription dispensed and shipped. Patients who have completed prior titration and supply recent labs often receive their prescription within three to five business days.